GlassScriptPhysician profile
Michael I Zuflacht
NPI 1417938507
$19,626.95
in general payments reported to CMS, 2019-2025
56 companies · $974 in 2025
The $974 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $2,335 · 2021: $2,640 · 2022: $3,878 · 2023: $4,328 · 2024: $3,778 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,897 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,896.92 |
| Education | $183.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,155.87 | 2019-2024 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,705.40 | 2019-2025 | |
| Ucb, INC. | $1,561.18 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Celgene Corporation | $1,458.46 | 2022-2025 | Zeposia |
| Abbvie INC. | $1,059.31 | 2021-2025 | Ubrelvy, Qulipta |
| Neurocrine Biosciences, INC. | $1,043.33 | 2020-2024 | Ingrezza, Ongentys |
| Genentech USA, INC. | $931.37 | 2019-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $874.74 | 2023-2025 | |
| Amgen INC. | $810.40 | 2019-2024 | Enbrel, Otezla |
| Teva Pharmaceuticals USA, INC. | $782.51 | 2019-2024 | Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $742.60 | 2019-2023 | Nuplazid |
| Argenx US, INC. | $491.38 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Pfizer INC. | $467.54 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $455.23 | 2019-2022 | |
| Livanova USA, INC. | $396.13 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zuflacht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.